Möchten Sie immer auf dem neuesten Stand bleiben?

DEINOVE has developed a unique bioproduction process that leads to the first 100% pure Phytoene with an anti-aging action which mechanism of action has been discovered and reveals a target of choice...

Georges GAUDRIAULT, Scientific Director of DEINOVE, will give a talk at the ECCMID, at the ‘Therapeutics pipeline corner’, on this coming Sunday, April 14th, in Amsterdam.He will describe the progress...

Novel antibiotics: DEINOVE signs an agreement with the Institut Pasteur to explore the potential of new targeted strains The Institut Pasteur will provide a selection of strains for the DEINOVE...

Finalization of the acquisition of DNV3837, a promising antibiotic for treating severe gastrointestinal infections caused by Clostridium difficile, expected to begin Phase II in mid-2019Successful...

DEINOVE passes the first milestone of the AGIR programm and receives €1.5m from Bpifrance The robotic platform for extracting and screening antibiotic activities from bacterial strains is now...

DEINOVE prépare l’entrée en Phase II du DNV3837 dans les infections à Clostridium difficile avec un partenaire-clé Le design de l’essai a été optimisé pour maximiser les chances de démontrer...

Deinove is preparing initiation of Phase II for DNV3837 in Clostridium difficile infections, with a key partner The test design has been improved for a better assessment of DNV3837 effectiveness in...

Un nouveau site Internet pour souligner la stratégie d'innovation radicale de DEINOVE Le nouveau site Internet de DEINOVE fait évoluer la présentation des activités et l'identité visuelle de...

A new website to highlight DEINOVE's disruptive innovation strategy The new DEINOVE website displays an updated presentation of DEINOVE's corporate activities and identityIt illustrates the...

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} DEINOVE WILL MARKET A 2ND PROPRIETARY...